Therapeutic outcome of diphencyprone and its correlation with serum cytokine profile in alopecia areata.

Therapeutic outcome of diphencyprone and its correlation with serum cytokine profile in alopecia areata.:

Related Articles

Therapeutic outcome of diphencyprone and its correlation with serum cytokine profile in alopecia areata.

J Dermatolog Treat. 2020 Apr 06;:1-20

Authors: Pm R, R S, Rajappa M, Chandrashekar L

Abstract

INTRODUCTION: Diphencyprone (DPCP) is considered as the first line of management in severe and extensive alopecia areata. The present study aims to evaluate the effectiveness of DPCP in alopecia areata and identify various prognostic factors and biomarkers associated with clinical response.

MATERIALS AND METHODS: The study included participants with extensive alopecia areata (>30% scalp hair loss) treated with DPCP. Participants with Macdonald Hull and Norris grade 3 and 4 at the end of 6 months were considered as responders. We performed cytokine analysis prior and post-therapy. The protocol was registered with CTRI(REF/2017/09/015424)Results: The response rate was 54.5%. Longer disease duration, nail involvement, high severity of alopecia tool (SALT) scores were associated with non-response. There was no significant difference in the cytokine levels among responders and non-responders before therapy. Among the responders, we found a significant decrease in IFN-γ, IL-17A, IL-9, TGF-β and IL-13 except for IL-4, which significantly increased whereas, among the non-responders, only IL-17A and IL-13 levels have reduced considerably.

DISCUSSION: Diphencyprone reduced the level of Th1, Th17 and Th9 cytokines and increased the level of Th2 cytokines (IL-4) in the present study, which induced remission and promoted hair regrowth.

PMID: 32249656 [PubMed - as supplied by publisher]